Skip to main content
Smart Investors Daily
LA

NASDAQ · LAB

Standard BioTools Inc.

Healthcare · Medical - Devices

$0.71

Up+$0.02 (+2.71%)

Updated Sep 30, 2026, 5:20 PM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
567.23M
P/E ratio
-4.4
Dividend yield
0.00%
52-week range
$0.63 – $1.72
Volume
173.44K
Avg. volume
1.65M

Price performance · LAB

LAB price history

1M range · 0 trading sessions · Daily adjusted prices

LAB does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest LAB news

The latest Smart Investors Daily articles mentioning LAB.

LAB research

Overview

Company profile and research snapshot.

Company profile

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$3.25
Implied upside
—
Analysts
—
LAB recent ratings
DateFirmRatingTarget
Nov 5, 2025TD CowenHold—
Feb 27, 2025KeybancSector Weight—
Oct 31, 2024TD CowenBuy—
Aug 1, 2024TD CowenBuy—
Apr 16, 2024TD CowenBuy—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.